• Explore /
  • Poster
  • / Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with <em>MET</em> amplification (<em>MET</em>amp).

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).

Abstract Video & Slides Poster

Authors

Xiuning Le

Xiuning Le

The University of Texas MD Anderson Cancer Center, Houston, TX

Xiuning Le , Luis G. Paz-Ares , Jan Van Meerbeeck , Santiago Viteri , Carlos Cabrera Galvez , David Vicente Baz , Young-Chul Kim , Jin-Hyoung Kang , Karl-Maria Schumacher , Niki Karachaliou , Svenja Adrian , Rolf Bruns , Paul K. Paik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02864992

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9021)

DOI

10.1200/JCO.2021.39.15_suppl.9021

Abstract #

9021

Abstract Disclosures

Similar Posters

First Author: Harry J.M. Groen

Poster

2023 ASCO Annual Meeting

Long-term outcomes of tepotinib in patients with <em>MET</em> exon 14 skipping NSCLC from the VISION study.

Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.

First Author: Paul K. Paik

First Author: Xiuning Le

First Author: Rebecca Suk Heist